ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NUWE / forecast
NXL (32) VBIO (36) NDRA (36) IRIX (27) ⌘ Pro Terminal →

Nuwellis Inc. (NUWE) 12-Month Stock Forecast & Price Target Cone

$5.18 -8.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.09

Nuwellis Inc. (NUWE) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NUWE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NUWE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nuwellis Inc. (NASDAQ: NUWE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.18 (-8.80% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUWE ranks #708 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NUWE compare to NXL and VBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NUWE carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NUWE leads on earnings multiple (N/A) while NUWE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NUWE?
▼

Per NUWE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001506492), Nuwellis Inc. generated $8.3M in revenue (-5.4% YoY), -$17.5M in net income, and -$10.9M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.09 (-1.77%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (8)SEC (7)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$182 Bull$5 Base$4 Bear
📬 FREE NUWE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUWE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY NUWE SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 62% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
25
Grade E$0.67-16.4% Next Q
Q2 (-2Q)
28
Grade E$0.56+866.1% Next Q
Q3 (-1Q)
30
Grade E$5.41-4.3% Next Q
Current
33
Grade E$5.18-8.9% Hist 90D α
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NUWE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NUWE currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.34) and Max Pain ($5.44) forces dealer call-delta covering toward $181.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUWE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUWE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NUWE Position Size: $10,000

Shares at $5.18: 1930.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $3.59
$6,931
$-3,069 (-30.7%)
12M Consensus BaseTarget $4.60
$8,880
$-1,120 (-11.2%)
12M Bull Case BreakoutTarget $181.55
$350,483
+$340,483 (+3404.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$574%A
Goldman SachsSector Coverage LeadUNDERPERFORM$17169%B
JP MorganUS Large-Cap ResearchSELL$458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUWE)

  • ✓Walkthrough of NUWE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NUWE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.79%⚡ TESTING RESISTANCE
2026-11-03O $5.78H $5.78L $5.18C $5.18VOL 311.4K
RES: $7.19SUP: $0.21SMA50: $1.34SMA200: $26.25
$121.2$88.44$55.68$22.91$-9.85RES $7.19SUP $0.21$5.182026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUWE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUWE Butterfly Map → + Track NUWE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -5.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NUWE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUWE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUWE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUWE)

Health Care Rank #708 of 1015 ⚔️ NXL vs NUWE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NUWE vs. NXL, VBIO, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nuwellis Inc. (NUWE) ranks #708 by composite RQD confidence (33/100, grade E) and #989 by equity capitalization ($2.3M). Within this direct 5-issuer industry benchmark cohort, NUWE leads on earnings valuation at N/A trailing P/E, while NUWE leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. VBIO currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with NUWE at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NUWE ACTIVE
Nuwellis Inc.
E 33/100 — 62.0% -35.0% -8.80% $2.3M Benchmark Subject
NXL
Nexalin Technology Inc.
E 32/100 — 79.7% -35.0% -5.94% $1.8M /nxl-vs-nuwe →
VBIO
Valion Bio Inc.
D- 36/100 — — -35.0% -3.47% $1.2M /vbio-vs-nuwe →
NDRA
ENDRA Life Sciences Inc.
D- 36/100 — — -35.0% +1.05% $7.1M /ndra-vs-nuwe →
IRIX
IRIDEX Corporation
E 27/100 — 36.5% -35.0% +1.33% $12.5M /irix-vs-nuwe →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001506492 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuwellis Inc. (NUWE) reported GAAP revenue of $8.3M (-5.4% vs. FY2024 revenue of $8.7M , and -6.7% cumulative change since FY2023) , GAAP net income of -$17.5M, operating cash flow of -$10.8M, and free cash flow of -$10.9M (-12.9% YoY). On the balance sheet, NUWE closed FY2025 with $6.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.3M -$17.5M -$10.8M -$10.9M $6.1M —
FY2024 (FY) 2024-12-31 $8.7M -$11.2M -$9.6M -$9.7M $9.9M —
FY2023 (FY) 2023-12-31 $8.9M -$20.2M -$17.9M -$17.9M — —

3. NUWE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUWE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nuwellis Inc. (NASDAQ: NUWE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.18 (-8.80% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUWE ranks #708 in composite RQD confidence.

How does NUWE compare to NXL and VBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NUWE carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NUWE leads on earnings multiple (N/A) while NUWE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUWE?

Per NUWE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001506492), Nuwellis Inc. generated $8.3M in revenue (-5.4% YoY), -$17.5M in net income, and -$10.9M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUWE trading relative to its 50-day, 200-day, and 52-week technical levels?

NUWE last traded at $5.18 (-8.80% on volume of 72,128 shares), positioning the stock +286.57% above its 50-day simple moving average ($1.34) and -80.27% below its 200-day simple moving average ($26.25). Across its 52-week range of $0.32 to $172.90, NUWE sits at the 2.8% percentile with a 14-day RSI of 88.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($4.53 to $5.83).

Direct Sub-Reports: NUWE RQD Cockpit NUWE 12M Forecast NUWE Earnings & Move NUWE Dividends & DRIP NUWE Insiders & 13F NUWE Whale Options NUWE Profit Sankey NUWE News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

NUWE — Nuwellis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nuwellis Inc. (NUWE) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.18 (-8.80% 1D, market capitalization $2.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 62.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nuwellis Inc. (NUWE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It operates with a market capitalization of $0.0B in that profile field. Per the market data, the company reports a gross margin of 62%, which is consistent with a product or service business that earns revenue above its direct cost base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nuwellis Inc. (NUWE) reported $8.3M in annual revenue (up from $8.7M in FY2024, -5.4% YoY) and -$17.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.9M revenue, -$20.2M net income) through FY2025, NUWE scaled operating cash flow to -$10.8M and free cash flow to -$10.9M, backed by $6.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.32 – $172.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — The sector is Health Care and the industry is Biotechnology: Electromedical & Electrotherapeutic Apparatus, but the source does not establish sector correlations or second-order bottlenecks. A prospective investor should watch whether the pediatric narrative in the news feed translates into reported revenue, since the FY 2025 revenue of $8.3M shows a declining trend.

  • Key Question #1: Can NUWE sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.3M and free cash flow of -$10.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NUWE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NUWE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nuwellis Inc. (NUWE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NUWE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NUWE Bull vs. Bear Conversation Board — What's Your Call at $5.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NUWE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NUWE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $7.21 (+26.9%)
📌 Pinned Debate

Pediatric growth headlines and a reported 87% survival rate in a 91-child kidney-support study are driving momentum and attention in th

Pediatric growth headlines and a reported 87% survival rate in a 91-child kidney-support study are driving momentum and attention in the stock.. When you look under the hood at NUWE, Fundamental Cash Engine is 8/20 with 62.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $172.90. My 12M target is $7.21.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 8/20 institutional whale-flow stock at $5.68 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.26 (-25.0%)
Spot @ $5.68

Revenue has declined to $8.3M while FY 2025 net loss of -$17.5M, FCF of -$10.9M, and year-end cash of $1.1M point to a stressed balance

Here is the bear case nobody on the bull side wants to address on NUWE: Revenue has declined to $8.3M while FY 2025 net loss of -$17.5M, FCF of -$10.9M, and year-end cash of $1.1M point to a stressed balance sheet.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.

LIVE TAPE